Phase II Single Arm Study of IMC-1121B in Patients With Metastatic Renal Cell Carcinoma With Disease Progression on or Intolerance to Tyrosine Kinase Inhibitor Therapy.
Phase of Trial: Phase II
Latest Information Update: 25 Jul 2014
At a glance
- Drugs Ramucirumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 02 Feb 2012 Actual initiation date changed from Mar 2007 to Nov 2007 as reported by ClinicalTrials.gov.
- 05 Oct 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 05 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.